165 related articles for article (PubMed ID: 33124186)
21. Somatic mutations in DCC are associated with genomic instability and favourable outcomes in melanoma patients treated with immune checkpoint inhibitors.
Li Y; Wang Q; Chen Y; Zhao L
Br J Cancer; 2022 Nov; 127(8):1411-1423. PubMed ID: 35871235
[TBL] [Abstract][Full Text] [Related]
22. High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade.
Onieva JL; Xiao Q; Berciano-Guerrero MÁ; Laborda-Illanes A; de Andrea C; Chaves P; Piñeiro P; Garrido-Aranda A; Gallego E; Sojo B; Gálvez L; Chica-Parrado R; Prieto D; Pérez-Ruiz E; Farngren A; Lozano MJ; Álvarez M; Jiménez P; Sánchez-Muñoz A; Oliver J; Cobo M; Alba E; Barragán I
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012390
[TBL] [Abstract][Full Text] [Related]
23. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
[TBL] [Abstract][Full Text] [Related]
24. Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy.
Miao YR; Liu CJ; Hu H; Yang M; Guo AY
Cells; 2022 Sep; 11(18):. PubMed ID: 36139377
[TBL] [Abstract][Full Text] [Related]
25. SERS Multiplex Profiling of Melanoma Circulating Tumor Cells for Predicting the Response to Immune Checkpoint Blockade Therapy.
Li J; Wuethrich A; Zhang Z; Wang J; Lin LL; Behren A; Wang Y; Trau M
Anal Chem; 2022 Oct; 94(42):14573-14582. PubMed ID: 36222247
[TBL] [Abstract][Full Text] [Related]
26. Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy.
Gong X; Karchin R
Sci Rep; 2023 Jan; 13(1):950. PubMed ID: 36653470
[TBL] [Abstract][Full Text] [Related]
27. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma.
de Azevedo RA; Shoshan E; Whang S; Markel G; Jaiswal AR; Liu A; Curran MA; Travassos LR; Bar-Eli M
Oncoimmunology; 2020 Dec; 9(1):1846915. PubMed ID: 33344042
[TBL] [Abstract][Full Text] [Related]
28. Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma.
Lelliott EJ; Mangiola S; Ramsbottom KM; Zethoven M; Lim L; Lau PKH; Oliver AJ; Martelotto LG; Kirby L; Martin C; Patel RP; Slater A; Cullinane C; Papenfuss AT; Haynes NM; McArthur GA; Oliaro J; Sheppard KE
Cancer Immunol Res; 2021 Feb; 9(2):136-146. PubMed ID: 33303574
[TBL] [Abstract][Full Text] [Related]
29.
Ibáñez-Molero S; van Vliet A; Pozniak J; Hummelink K; Terry AM; Monkhorst K; Sanders J; Hofland I; Landeloos E; Van Herck Y; Bechter O; Kuilman T; Zhong W; Marine JC; Wessels L; Peeper DS
Oncoimmunology; 2022; 11(1):2139074. PubMed ID: 36465485
[TBL] [Abstract][Full Text] [Related]
30. Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot.
Janjigian YY; Wolchok JD; Ariyan CE
Cancer Cell; 2021 Jun; 39(6):738-742. PubMed ID: 34129818
[TBL] [Abstract][Full Text] [Related]
31. CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
[TBL] [Abstract][Full Text] [Related]
32. CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade.
Wang G; Chow RD; Zhu L; Bai Z; Ye L; Zhang F; Renauer PA; Dong MB; Dai X; Zhang X; Du Y; Cheng Y; Niu L; Chu Z; Kim K; Liao C; Clark P; Errami Y; Chen S
Cancer Discov; 2020 Dec; 10(12):1912-1933. PubMed ID: 32887696
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
Kim KB; Soroceanu L; de Semir D; Millis SZ; Ross J; Vosoughi E; Dar AA; Nosrati M; Desprez PY; Ice R; Chen M; Chetal K; Bhattacharjee A; Moretto J; Leong SP; Singer MI; Parrett BM; Minor DR; McAllister S; Miller JR; Salomonis N; Kashani-Sabet M
J Invest Dermatol; 2021 Aug; 141(8):2028-2036.e2. PubMed ID: 33610559
[TBL] [Abstract][Full Text] [Related]
34. IL-5-producing CD4
Blomberg OS; Spagnuolo L; Garner H; Voorwerk L; Isaeva OI; van Dyk E; Bakker N; Chalabi M; Klaver C; Duijst M; Kersten K; Brüggemann M; Pastoors D; Hau CS; Vrijland K; Raeven EAM; Kaldenbach D; Kos K; Afonina IS; Kaptein P; Hoes L; Theelen WSME; Baas P; Voest EE; Beyaert R; Thommen DS; Wessels LFA; de Visser KE; Kok M
Cancer Cell; 2023 Jan; 41(1):106-123.e10. PubMed ID: 36525971
[TBL] [Abstract][Full Text] [Related]
35. High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade.
Chua KLM; Fehlings M; Yeo ELL; Nardin A; Sumatoh H; Chu PL; Nei WL; Ong EHW; Woo WY; Low KP; Wang H; Poon DJJ; Liang ZG; Yao K; Huang L; Toh CK; Ang MK; Farid M; Cheng XM; Kanesvaran R; Dent R; Wee JTS; Lim TKH; Iyer NG; Tan DSW; Soo KC; Newell EW; Chua MLK
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):70-80. PubMed ID: 32544576
[TBL] [Abstract][Full Text] [Related]
36. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
McGrail DJ; Pilié PG; Rashid NU; Voorwerk L; Slagter M; Kok M; Jonasch E; Khasraw M; Heimberger AB; Lim B; Ueno NT; Litton JK; Ferrarotto R; Chang JT; Moulder SL; Lin SY
Ann Oncol; 2021 May; 32(5):661-672. PubMed ID: 33736924
[TBL] [Abstract][Full Text] [Related]
37. Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically.
Chafe SC; McDonald PC; Saberi S; Nemirovsky O; Venkateswaran G; Burugu S; Gao D; Delaidelli A; Kyle AH; Baker JHE; Gillespie JA; Bashashati A; Minchinton AI; Zhou Y; Shah SP; Dedhar S
Cancer Immunol Res; 2019 Jul; 7(7):1064-1078. PubMed ID: 31088846
[TBL] [Abstract][Full Text] [Related]
38. Clonal tracing reveals diverse patterns of response to immune checkpoint blockade.
Gu SS; Wang X; Hu X; Jiang P; Li Z; Traugh N; Bu X; Tang Q; Wang C; Zeng Z; Fu J; Meyer C; Zhang Y; Cejas P; Lim K; Wang J; Zhang W; Tokheim C; Sahu AD; Xing X; Kroger B; Ouyang Z; Long H; Freeman GJ; Brown M; Liu XS
Genome Biol; 2020 Oct; 21(1):263. PubMed ID: 33059736
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of UBA6 by inosine augments tumour immunogenicity and responses.
Zhang L; Jiang L; Yu L; Li Q; Tian X; He J; Zeng L; Yang Y; Wang C; Wei Y; Jiang X; Li J; Ge X; Gu Q; Li J; Wu D; Sadler AJ; Yu D; Xu D; Gao Y; Yuan X; He B
Nat Commun; 2022 Sep; 13(1):5413. PubMed ID: 36109526
[TBL] [Abstract][Full Text] [Related]
40. Photothermal therapies to improve immune checkpoint blockade for cancer.
Balakrishnan PB; Sweeney EE; Ramanujam AS; Fernandes R
Int J Hyperthermia; 2020 Dec; 37(3):34-49. PubMed ID: 33426992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
